Association between Human Leukocyte Antigens (HLA-A, -B, and -DR) and end-stage renal disease in Kuwaiti patients awaiting transplantation

References

• Jha V. Current status of end-stage renal disease care in South Asia. Ethn Dis. 2009;19(S1):27–32
   Google Scholar
• Gupta R, Mohammed AM, Alenizi EK, Ben Nekhi A. Bone mineral density in Kuwaiti patients with end-stage renal disease. Med Princ Pract. 2011;20:156–158
   PubMed Web of Science ®Google Scholar
• Al-Taie LH, Al-Ghurabi BH, Al-Hassan AA, Dager AJ. Frequency of HLA-A and B antigens in Iraqi patients with end-stage renal disease preparing for transplantation. Iraqi Postgraduate Med J. 2012;11:642–648
   Google Scholar
• El-Reshaid K, Johny KV, Sugathan TN, Hakim A, Georgous M, Nampoory MRN. Endstage renal disease and renal replacement therapy in Kuwait – Epidemiological profile over the past 4 ½ years. Nephrol Dial Transplant. 1994;9:532–538
   PubMed Web of Science ®Google Scholar
• Al-Eisa A, Naseef M, Al-Hamad N, Pinto R, Al-Shimeri N, Tahmaz M: Chronic renal failure in Kuwaiti children: An eight-year experience. Pediatr Nephrol. 2005;20:1781–1785
   Google Scholar
• Crispim JC, Mendes-Júnior CT, Wastowski IJ, et al. HLA polymorphisms as incidence factor in the progression to end-stage renal disease in Brazilian patients awaiting kidney transplant. Transplant Proc. 2008;40:1333–1336
   PubMed Web of Science ®Google Scholar
• Walter WG, Neaton JD, Cutler JA. Renal function change in hypertensive members of the multiple risk factor intervention trial: Racial and treatment effects. JAMA. 1992;268:3085–3091
   Google Scholar
• Locatelli F, Del Vecchio L. National history and factors affecting the progression of chronic renal failure. In: El Nahas AM, Harris KPG, Anderson S, eds. Mechanisms and Management of Progressive Renal Failure. London, UK: Oxford University Press; 2000:20–79
   Google Scholar
• Rivera SP, Márquez G, Cipriani AM, et al. HLA class I association with progression to end-stage renal disease in patients from Zulia, Venezuela. Inmunologia. 2012;21:1–6
   Google Scholar
• Neefjes J, Jongsma ML, Paul P, Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol. 2011;11(12):823–836
   PubMed Web of Science ®Google Scholar
• Shiina T, Inoko H, Kulski JK. An update of the HLA genomic region, locus information and disease associations. Tissue Antigens. 2004;64:631–649
   PubMedGoogle Scholar
• Karahan GE, Seyhun Y, Oguz FS, et al. Impact of HLA on the underlying primary diseases in Turkish patients with end-stage renal disease. Ren Fail. 2009;31:44–49
   PubMed Web of Science ®Google Scholar
• Davood PP, Farhadi N, Najafizadeh M. Protective and Susceptible HLA Class I genes in patients with end-stage renal disease. Res J Biol Sci. 2008;3:1344–1346
   Google Scholar
• Doxiadis II, De Lange P, De Vries E, Persijn GG. Protective and susceptible HLA polymorphisms in IgA nephropathy patients with ESRD. Tissue Antigens. 2001;57:344–347
   Google Scholar
• Karahan GE, Kekik C, Oguz FS, et al. Association of HLA phenotypes of end-stage renal disease patients preparing for first transplantation with anti-HLA antibody status. Ren Fail. 2010;32:380–383
   Web of Science ®Google Scholar
• Heise E, Manning C, Thacker L. HLA phenotypes of ESRD patients are risk factors in the panel-reactive antibody reponse. Clin Transplant. 2001;6:22–27
   Google Scholar
• Clark B, Unsworth DJ. HLA and kidney transplantation. J Clin Pathol. 2010;63:21–25
   Google Scholar
• Terasaki PI, Park MS. Micro-droplet lymphocyte cytotoxicity test. In: Ray JG, ed. Manual of Tissue Typing Techniques. Bethesda: NIH; 1980:92–103
   Google Scholar
• Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379(9811):165–180
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1–S266
   PubMed Web of Science ®Google Scholar
• El-Reshaid W, El-Reshaid K, Kapoor M, Hakim A. Chronic renal disease in Kuwaiti nationals: A prospective study during the past 4 years. Ren Fail. 2005;27(2):227–233
   PubMed Web of Science ®Google Scholar
• Psillas G, Daniilidis M, Gerofotis A, et al. Sudden bilateral sensorineural hearing loss associated with HLA A1-B8-DR3 haplotype. Case Rep Otolaryngol. 2013;2013:590157 (1–4)
   Google Scholar
• Howell WM. HLA and disease: Guilt by association. Int J Immunogenet. 2014;41(1):1–12
   Google Scholar
• Price P, Witt C, Allcock R, et al. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev. 1999;167:257–274
   PubMed Web of Science ®Google Scholar
• Aly TA, Eller E, Ide A, et al. Multi-SNP analysis of MHC region: Remarkable conservation of HLA-A1-B8-DR3 haplotype. Diabetes. 2006;55:1265–1269
   Google Scholar
• Wilson AG, De Vries N, Pociot F, et al. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med. 1993;77:557–560
   Google Scholar
• Lio D, Candore G, Colombo A, et al. A genetically determined high setting of TNF-alpha influences immunologic parameters of HLA-B8,DR3 positive subjects: Implications for autoimmunity. Hum Immunol. 2001;62:705–713
   Google Scholar
• Lawley TJ, Hall RP, Fauci AS, Katz SI, Hamburger MI, Frank MM. Defective Fc-receptor functions associated with the HLA-B8/DRw3 haplotype: Studies in patients with dermatitis herpetiformis and normal subjects. N Engl J Med. 1981;304:185–192
   PubMed Web of Science ®Google Scholar
• Caruso C, Candore G, Modica MA, et al. Major histocompatibility complex regulation of cytokine production. J Interferon Cytokine Res. 1996;16:983–988
   PubMedGoogle Scholar
• Andresdottir MB, Haasnoot GW, Persijn GG, Claas FH. HLA-B8, DR3: A new risk factor for graft failure after renal transplantation in patients with underlying immunoglobulin A nephropathy. Clin Transplant. 2009;23(5):660–665
   Google Scholar
• Colucci AT, Di Lorenzo G, Ingrassia A, et al. Blood antiphospholipid antibody levels are influenced by age, sex and HLA-B8,DR3 phenotype. Exp Clin Immunogenet. 1992;9:72–79
   PubMedGoogle Scholar
• Candore G, Modica MA, Lio D, et al. Pathogenesis of autoimmune diseases associated with 8.1 ancestral haplotype: A genetically determined defect of C4 influences immunological parameters of healthy carriers of the haplotype. Biomed Pharmacother. 2003;57:274–277
   PubMedGoogle Scholar
• Donia AF, Ismail AM, Moustafa FH. HLA class I typing in Egyptian childhood minimal change nephritic syndrome. J Nephrol. 2008;21:734–737
   Google Scholar
• El-Gezawy EM, Baset HA, Nasif KA, et al. Human leukocyte antigens as a risk factor for the primary diseases leading to end stage renal disease in Egyptian patients. Egypt J Immunol. 2011;18(2):13–21
   Google Scholar
• Almogren A, Shakoor Z, Hamam KD. Human leucocyte antigens: Their association with end-stage renal disease in Saudi patients awaiting transplantation. Br J Biomed Sci. 2012;69(4):159–163
   PubMed Web of Science ®Google Scholar
• Chen DF. Relationship between human leukocyte antigen determinants and courses of HBV infection in Caucasian patients with ESRD. Scand J Gastroenteol. 1996;31:1211–1215
   PubMed Web of Science ®Google Scholar
• Freedman BI, Spray BJ, Dunston GM, Heise ER. HLA associations in end-stage renal disease due to membranous glomerulonephritis: HLA-DR3 associations with 15 progressive renal injury. Southeastern Organ Procurement Foundation. Am J Kidney Dis. 1994;23(6):797–802
   PubMed Web of Science ®Google Scholar
• Pérez-Luque E, Malacara JM, Olivo-Díaz A, et al. Contribution of HLA class II genes to end stage renal disease in Mexican patients with type 2 diabetes mellitus. Hum Immunol. 2000;61(10):1031–1038
   Google Scholar